Imagin Medical Inc.

Equities

IME

CA45250L2049

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 02:29:20 2024-02-02 pm EST			5-day change	1st Jan Change
0.015 ^CAD	-.--%		-.--%	-70.00%

2023	Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
2023	Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI

Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020

February 26, 2021 at 04:31 pm EST

Imagin Medical Inc. announced earnings results for the first quarter ended December 31, 2020. For the first quarter, the company announced net loss was CAD 562,260 compared to CAD 1.241 million a year ago. Basic loss per share from continuing operations was CAD 0.06 compared to CAD 0.18 a year ago.

Latest news about Imagin Medical Inc.

Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-28	CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-24	CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-10	CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-22	CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt	22-12-21	CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-29	CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-27	CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-18	CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	21-12-24	CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt	21-12-23	CI
Imagin Medical Inc. Announces Board Changes	21-11-08	CI
Imagin Medical Inc. announced that it has received $2.9005 million in funding	21-08-25	CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-20	CI
Imagin Medical Inc. Reports the Final Design of the i/Blue Imaging System Is on Target to Be Demonstrated At the American Urology Association Annual Meeting in September	21-08-17	CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-26	CI
Imagin Medical Reports Company on Schedule for Product Demonstration	21-05-19	CI
Imagin Medical Inc. Reports Continued Progress Towards Commercial-Stage Manufacturing Capability with Lighthouse Imaging	21-03-16	CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020	21-02-26	CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	20-12-22	CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt	20-12-21	CI
Transcript : Imagin Medical Inc. - Special Call	20-10-29
Imagin Medical Inc. announced that it expects to receive $3 million in funding	20-10-21	CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	20-08-28	CI
Imagin Medical to Begin Testing of i/BLUE TM Imaging System on Anatomical Bladder Models	20-07-15	CI
Transcript : Imagin Medical Inc., Q2 2020 Earnings Call, May 28, 2020	20-05-28

Chart Imagin Medical Inc.

Duration

Period

More charts

Company Profile

Imagin Medical Inc. is a urologic oncology company. It is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that will deliver bipolar, radio frequency energy through a distinctive coil electrode, or cage. It enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.

Sector

Biotechnology & Medical Research

Calendar

2024-04-27 - American Urological Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Medical Devices

	1st Jan change	Capi.
IMAGIN MEDICAL INC.	-70.00%	119K
MIMEDX GROUP, INC.	-28.51%	925M
NIBEC CO., LTD.	-20.60%	128M
COLLPLANT BIOTECHNOLOGIES LTD.	-7.82%	67.46M
KIM FOREST ENTERPRISE CO., LTD.	+6.64%	60.58M
NOVACYT	+14.87%	61.68M
BONUS BIOGROUP LTD.	+0.60%	51.45M

Bio Medical Devices